Genetic markers that may predict response to anti-TNF treatment in inflammatory bowel disease
Looks at whether genes predict anti-TNF response in adults with Crohn disease or ulcerative colitis.
Plain-language title generated from the registry record
Registry title: Individualizing Anti-TNF Therapy in Patients With Inflammatory Bowel Disease
Key facts
- Where
- Tel Aviv, IsraelSee the site
Where in Israel
- Dep. of Gastroenterology, Tel Aviv Sourasky Medical CenterTel Aviv, IsraelTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Shmuel Kivity, MD
- Trial code
- NCT07644117
- Record updated
- 12 June 2026
- Original description
This observational study aims to identify genes that may affect how patients with inflammatory bowel disease respond to anti-TNF treatment and why some patients lose response to treatment over time. The study will examine whether genetic markers can help predict which patients are more likely to respond to anti-TNF therapy.Read full original descriptionShow less
Individualizing Anti-TNF Therapy in Patients With Inflammatory Bowel Disease: Pre-Treatment Prediction of Immunogenicity and Response. A Prospective Observational Study.
This observational study aims to identify genes that may affect how patients with inflammatory bowel disease respond to anti-TNF treatment and why some patients lose response to treatment over time. The study will examine whether genetic markers can help predict which patients are more likely to respond to anti-TNF therapy.
Participants who have not previously received anti-TNF treatment and are about to start advanced therapy will provide a blood sample to test for the genetic markers. Participants will also undergo regular assessments of current treatment, disease activity, and inflammatory markers during follow-up.
Inclusion: Established IBD: Crohn's disease (CD) or ulcerative colitis (UC); Anti-TNF naïve; Clinically active disease (HBI>5 for CD, p-MS≥ 3 for UC); Elevated inflammatory indices CRP>10 or fecal calprotectin>250.
Exclusion: Unable to provide informed consent; Anti-TNF experienced; Unable to complete the study protocol.